The balance of powers: Redox regulation of fibrogenic pathways in kidney injury

Redox Biology

Volumn 6, Issue , 2015, Pages 495-504

  Okamura, Daryl M ^a   Pennathur, Subramaniam ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chronic kidney disease; Fibrosis; Mass spectrometry; Oxidative stress; Oxidized amino acids

Indexed keywords

AMINO ACID; BIOLOGICAL MARKER; CATALASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; MYELOPEROXIDASE; PEROXIREDOXIN; POLYUNSATURATED FATTY ACID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOL; THIOREDOXIN REDUCTASE;

CELL FUNCTION; CELL STRUCTURE; DISEASE ASSOCIATION; DISEASE EXACERBATION; FIBROGENESIS; GENE OVEREXPRESSION; GLUCOSE METABOLISM; GLYCOXIDATION; HUMAN; IN VIVO STUDY; KIDNEY INJURY; LIPID OXIDATION; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHRONIC KIDNEY FAILURE; FIBROSIS; KIDNEY; METABOLISM; PATHOLOGY;

ANIMALS; FIBROSIS; HUMANS; KIDNEY; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84943144649     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2015.09.039     Document Type: Review

References (162)

1. Thannickal V.J. Oxygen in the evolution of complex life and the price we pay. Am. J. Respir. Cell Mol. Biol. 2008, 507-510.
2. Chawla L.S., Eggers P.W., Star R.A., Kimmel P.L. Acute kidney injury and chronic kidney disease as interconnected syndromes. New Engl. J. Med. 2014, 371(1):58-66.
3. McCullough P.A., Li S., Jurkovitz C.T., Stevens L., Collins A.J., Chen S.C., Norris K.C., McFarlane S., Johnson B., Shlipak M.G., et al. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am. Heart J. 2008, 156(2):277-283.
4. Chawla L.S., Kimmel P.L. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int. 2012, 82(5):516-524.
5. Forman H.J., Fukuto J.M., Torres M. Redox signaling: thiol chemistry defines which reactive oxygen and nitrogen species can act as second messengers. Am. J. Physiol. Cell Physiol. 2004, 287(2):C246-C256.
6. Kemp M., Go Y.M., Jones D.P. Nonequilibrium thermodynamics of thiol/disulfide redox systems: a perspective on redox systems biology. Free Radic. Biol. Med. 2008, 44(6):921-937.
7. Okamura D.M., Himmelfarb J. Tipping the redox balance of oxidative stress in fibrogenic pathways in chronic kidney disease. Pediatr. Nephrol. 2009, 24(12):2309-2319.
8. Rhee S.G., Bae Y.S., Lee S.R., Kwon J. Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. Sci. STKE 2000 2000, 53:PE1.
9. Lambeth J.D. NOX enzymes and the biology of reactive oxygen. Nat. Rev. Immunol. 2004, 4(3):181-189.
10. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007, 87(1):245-313.
11. Segal B.H., Davidson B.A., Hutson A.D., Russo T.A., Holm B.A., Mullan B., Habitzruther M., Holland S.M., Knight P.R. Acid aspiration-induced lung inflammation and injury are exacerbated in NADPH oxidase-deficient mice. Am. J. Physiol. Lung.: Cell Mol. Physiol. 2007, 292(3):L760-L768.
12. Gao X.P., Standiford T.J., Rahman A., Newstead M., Holland S.M., Dinauer M.C., Liu Q.H., Malik A.B. Role of NADPH oxidase in the mechanism of lung neutrophil sequestration and microvessel injury induced by Gram-negative sepsis: studies in p47phox-/- and gp91phox-/- mice. J. Immunol. 2002, 168(8):3974-3982.
13. Morgenstern D.E., Gifford M.A., Li L.L., Doerschuk C.M., Dinauer M.C. Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus. J. Exp. Med. 1997, 185(2):207-218.
14. Kassim S.Y., Fu X., Liles W.C., Shapiro S.D., Parks W.C., Heinecke J.W. NADPH oxidase restrains the matrix metalloproteinase activity of macrophages. J. Biol. Chem. 2005, 280(34):30201-30205.
15. Snelgrove R.J., Edwards L., Williams A.E., Rae A.J., Hussell T. In the absence of reactive oxygen species, T cells default to a Th1 phenotype and mediate protection against pulmonary Cryptococcus neoformans infection. J. Immunol. 2006, 177(8):5509-5516.
16. Geiszt M., Leto T.L. The Nox family of NAD(P)H oxidases: host defense and beyond. J. Biol. Chem. 2004, 279(50):51715-51718.
17. Terada L.S. Specificity in reactive oxidant signaling: think globally, act locally. J. Cell Biol. 2006, 174(5):615-623.
18. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy, Heart Outcomes Prevention Evaluation Study Investigators, Lancet, 2000; 355,9200, pp. 253-259.
19. Takac I., Schroder K., Zhang L., Lardy B., Anilkumar N., Lambeth J.D., Shah A.M., Morel F., Brandes R.P. The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4. J. Biol. Chem. 2011, 286(15):13304-13313.
20. Block K., Gorin Y., Abboud H.E. Subcellular localization of Nox4 and regulation in diabetes. Proc. Natl. Acad. Sci. USA 2009, 106(34):14385-14390.
21. Eid A.A., Lee D.Y., Roman L.J., Khazim K., Gorin Y. Sestrin 2 and AMPK connect hyperglycemia to Nox4-dependent endothelial nitric oxide synthase uncoupling and matrix protein expression. Mol. Cell Biol. 2013, 33(17):3439-3460.
22. Shah A., Xia L., Goldberg H., Lee K.W., Quaggin S.E., Fantus I.G. Thioredoxin-interacting protein mediates high glucose-induced reactive oxygen species generation by mitochondria and the NADPH oxidase, Nox4, in mesangial cells. J. Biol. Chem. 2013, 288(10):6835-6848.
23. Block K., Eid A., Griendling K.K., Lee D.Y., Wittrant Y., Gorin Y. Nox4 NAD(P)H oxidase mediates Src-dependent tyrosine phosphorylation of PDK-1 in response to angiotensin II: role in mesangial cell hypertrophy and fibronectin expression. J. Biol. Chem. 2008, 283(35):24061-24076.
24. Ago T., Kuroda J., Pain J., Fu C., Li H., Sadoshima J. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ. Res. 2010, 106(7):1253-1264.
25. Lee D.Y., Wauquier F., Eid A.A., Roman L.J., Ghosh-Choudhury G., Khazim K., Block K., Gorin Y. Nox4 NADPH oxidase mediates peroxynitrite-dependent uncoupling of endothelial nitric-oxide synthase and fibronectin expression in response to angiotensin II: role of mitochondrial reactive oxygen species. J. Biol. Chem. 2013, 288(40):28668-28686.
26. Budanov A.V. Stress-responsive sestrins link p53 with redox regulation and mammalian target of rapamycin signaling. Antioxid. Redox Signal. 2011, 15(6):1679-1690.
27. Budanov A.V., Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008, 134(3):451-460.
28. Lee J.H., Budanov A.V., Talukdar S., Park E.J., Park H.L., Park H.W., Bandyopadhyay G., Li N., Aghajan M., Jang I., et al. Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3. Cell Metab. 2012, 16(3):311-321.
29. Sanli T., Linher-Melville K., Tsakiridis T., Singh G. Sestrin2 modulates AMPK subunit expression and its response to ionizing radiation in breast cancer cells. PLoS One 2012, 7(2):e32035.
30. Ashraf S., Gee H.Y., Woerner S., Xie L.X., Vega-Warner V., Lovric S., Fang H., Song X., Cattran D.C., Avila-Casado C., et al. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J. Clin. Investig. 2013, 123(12):5179-5189.
31. Eid A.A., Ford B.M., Bhandary B., de Cassia Cavaglieri R., Block K., Barnes J.L., Gorin Y., Choudhury G.G., Abboud H.E. Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury. Diabetes 2013, 62(8):2935-2947.
32. Eid A.A., Ford B.M., Block K., Kasinath B.S., Gorin Y., Ghosh-Choudhury G., Barnes J.L., Abboud H.E. AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J. Biol. Chem. 2010, 285(48):37503-37512.
33. Jha J.C., Gray S.P., Barit D., Okabe J., El-Osta A., Namikoshi T., Thallas-Bonke V., Wingler K., Szyndralewiez C., Heitz F., et al. Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. J. Am. Soc. Nephrol. 2014, 25(6):1237-1254.
34. Holterman C.E., Thibodeau J.F., Towaij C., Gutsol A., Montezano A.C., Parks R.J., Cooper M.E., Touyz R.M., Kennedy C.R. Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. J. Am. Soc. Nephrol. 2014, 25(4):784-797.
35. Wang H., Chen X., Su Y., Paueksakon P., Hu W., Zhang M.Z., Harris R.C., Blackwell T.S., Zent R., Pozzi A. p47(phox) contributes to albuminuria and kidney fibrosis in mice. Kidney Int. 2015, 87(5):948-962.
36. Eid A.A., Gorin Y., Fagg B.M., Maalouf R., Barnes J.L., Block K., Abboud H.E. Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes 2009, 58(5):1201-1211.
37. Piwkowska A., Rogacka D., Audzeyenka I., Jankowski M., Angielski S. High glucose concentration affects the oxidant-antioxidant balance in cultured mouse podocytes. J. Cell Biochem. 2011, 112(6):1661-1672.
38. Falke L.L., Gholizadeh S., Goldschmeding R., Kok R.J., Nguyen T.Q. Diverse origins of the myofibroblast-implications for kidney fibrosis. Nat. Rev. Nephrol. 2015, 11(4):233-244.
39. Jain M., Rivera S., Monclus E.A., Synenki L., Zirk A., Eisenbart J., Feghali-Bostwick C., Mutlu G.M., Budinger G.R., Chandel N.S. Mitochondrial reactive oxygen species regulate transforming growth factor-beta signaling. J. Biol. Chem. 2013, 288(2):770-777.
40. Okamura D.M., Bahrami N.M., Ren S., Pasichnyk K., Williams J.M., Gangoiti J.A., Lopez-Guisa J.M., Yamaguchi I., Barshop B.A., Duffield J.S., et al. Cysteamine modulates oxidative stress and blocks myofibroblast activity in CKD. J. Am. Soc. Nephrol. 2014, 25(1):43-54.
41. L. Alili, M. Sack, K. Puschmann, P. Brenneisen, Fibroblast-to-myofibroblast switch is mediated by NAD(P)H oxidase generated reactive oxygen species, Biosci. Rep, 2013.
42. Chen Y.T., Chang Y.T., Pan S.Y., Chou Y.H., Chang F.C., Yeh P.Y., Liu Y.H., Chiang W.C., Chen Y.M., Wu K.D., et al. Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibroblasts during peritoneal injury. J. Am. Soc. Nephrol. 2014, 25(12):2847-2858.
43. Manickam N., Patel M., Griendling K.K., Gorin Y., Barnes J.L. RhoA/Rho kinase mediates TGF-beta1-induced kidney myofibroblast activation through Poldip2/Nox4-derived reactive oxygen species. Am. J. Physiol. Renal. Physiol. 2014, 307(2):F159-F171.
44. A. Andersson-Sjoland, J.C. Karlsson, K. Rydell-Tormanen, ROS-induced endothelial stress contributes to pulmonary fibrosis through pericytes and Wnt signaling, Lab. Investig., 2015.
45. Montorfano I., Becerra A., Cerro R., Echeverria C., Saez E., Morales M.G., Fernandez R., Cabello-Verrugio C., Simon F. Oxidative stress mediates the conversion of endothelial cells into myofibroblasts via a TGF-beta1 and TGF-beta2-dependent pathway. Lab. Investig. 2014, 94(10):1068-1082.
46. Zhang X., Liang D., Guo L., Liang W., Jiang Y., Li H., Zhao Y., Lu S., Chi Z.H. Curcumin protects renal tubular epithelial cells from high glucose-induced epithelial-to-mesenchymal transition through Nrf2-mediated upregulation of heme oxygenase-1. Mol. Med. Rep. 2015, 12(1):1347-1355.
47. Kobayashi M., Sugiyama H., Wang D.H., Toda N., Maeshima Y., Yamasaki Y., Masuoka N., Yamada M., Kira S., Makino H. Catalase deficiency renders remnant kidneys more susceptible to oxidant tissue injury and renal fibrosis in mice. Kidney Int. 2005, 68(3):1018-1031.
48. Barnes J.L., Gorin Y. Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int. 2011, 79(9):944-956.
49. Bondi C.D., Manickam N., Lee D.Y., Block K., Gorin Y., Abboud H.E., Barnes J.L. NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J. Am. Soc. Nephrol. 2010, 21(1):93-102.
50. Attisano L., Wrana J.L. Signal transduction by the TGF-beta superfamily. Science 2002, 296(5573):1646-1647.
51. Schnaper H.W., Hayashida T., Poncelet A.C. It's a Smad world: regulation of TGF-beta signaling in the kidney. J. Am. Soc. Nephrol. 2002, 13(4):1126-1128.
52. Cucoranu I., Clempus R., Dikalova A., Phelan P.J., Ariyan S., Dikalov S., Sorescu D. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ. Res. 2005, 97(9):900-907.
53. Hecker L., Vittal R., Jones T., Jagirdar R., Luckhardt T.R., Horowitz J.C., Pennathur S., Martinez F.J., Thannickal V.J. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 2009, 15(9):1077-1081.
54. YouY.H., QuachT., SaitoR., PhamJ., and SharmaK.Metabolomics Reveals a Key Role for Fumarate in Mediating the Effects of NADPH Oxidase 4 in Diabetic Kidney Disease. Journal of the American Society of Nephrology: JASN.2015.
55. Sturrock A., Cahill B., Norman K., Huecksteadt T.P., Hill K., Sanders K., Karwande S.V., Stringham J.C., Bull D.A., Gleich M., et al. Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 290(4):L661-L673.
56. Waghray M., Cui Z., Horowitz J.C., Subramanian I.M., Martinez F.J., Toews G.B., Thannickal V.J. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. Faseb J. 2005, 19(7):854-856.
57. Qi W., Niu J., Qin Q., Qiao Z., Gu Y. Glycated albumin triggers fibrosis and apoptosis via an NADPH oxidase/Nox4-MAPK pathway-dependent mechanism in renal proximal tubular cells. Mol. Cell Endocrinol. 2015, 405:74-83.
58. Gorin Y. Nox4 as a potential therapeutic target for treatment of uremic toxicity associated to chronic kidney disease. Kidney Int. 2013, 83(4):541-543.
59. Shimizu H., Saito S., Higashiyama Y., Nishijima F., CREB Niwa T. NF-kappaB, and NADPH oxidase coordinately upregulate indoxyl sulfate-induced angiotensinogen expression in proximal tubular cells. Am. J. Physiol. Cell Physiol. 2013, 304(7):C685-C692.
60. Watanabe H., Miyamoto Y., Honda D., Tanaka H., Wu Q., Endo M., Noguchi T., Kadowaki D., Ishima Y., Kotani S., et al. p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int. 2013, 83(4):582-592.
61. Kim S.M., Kim Y.G., Jeong K.H., Lee S.H., Lee T.W., Ihm C.G., Moon J.Y. Angiotensin II-induced mitochondrial Nox4 is a major endogenous source of oxidative stress in kidney tubular cells. PLoS One 2012, 7(7):e39739.
62. Lin C.J., Wu V., Wu P.C., Wu C.J. Meta-analysis of the associations of p-cresyl sulfate (pcs) and indoxyl sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure. PLoS One 2015, 10(7):e0132589.
63. Han H., Zhu J., Zhu Z., Ni J., Du R., Dai Y., Chen Y., Wu Z., Lu L., Zhang R. p-Cresyl sulfate aggravates cardiac dysfunction associated with chronic kidney disease by enhancing apoptosis of cardiomyocytes. J. Am. Heart Assoc. 2015, 4(6):e001852.
64. Barreto F.C., Barreto D.V., Liabeuf S., Meert N., Glorieux G., Temmar M., Choukroun G., Vanholder R., Massy Z.A. and European Uremic Toxin Work G. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J. Am. Soc. Nephrol. 2009, 4(10):1551-1558.
65. Liabeuf S., Barreto D.V., Barreto F.C., Meert N., Glorieux G., Schepers E., Temmar M., Choukroun G., Vanholder R., Massy Z.A., et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol. Dial. Transplant. 2010, 25(4):1183-1191.
66. Babelova A., Avaniadi D., Jung O., Fork C., Beckmann J., Kosowski J., Weissmann N., Anilkumar N., Shah A.M., Schaefer L., et al. Role of Nox4 in murine models of kidney disease. Free Radic. Biol. Med. 2012, 53(4):842-853.
67. Nlandu Khodo S., Dizin E., Sossauer G., Szanto I., Martin P.Y., Feraille E., Krause K.H., de Seigneux S. NADPH-oxidase 4 protects against kidney fibrosis during chronic renal injury. J. Am. Soc. Nephrol. 2012, 23(12):1967-1976.
68. Ghezzi P., Bonetto V., Fratelli M. Thiol-disulfide balance: from the concept of oxidative stress to that of redox regulation. Antioxid. Redox Signal. 2005, 7(7-8):964-972.
69. Hamdane D., Kiger L., Dewilde S., Green B.N., Pesce A., Uzan J., Burmester T., Hankeln T., Bolognesi M., Moens L., et al. The redox state of the cell regulates the ligand binding affinity of human neuroglobin and cytoglobin. J. Biol. Chem. 2003, 278(51):51713-51721.
70. Jordan P.A., Gibbins J.M. Extracellular disulfide exchange and the regulation of cellular function. Antioxid. Redox Signal. 2006, 8(3-4):312-324.
71. Kerblat I., Drouet C., Chesne S., Marche P.N. Importance of thioredoxin in the proteolysis of an immunoglobulin G as antigen by lysosomal Cys-proteases. Immunology 1999, 97(1):62-68.
72. Reeves J.P., Bailey C.A., Hale C.C. Redox modification of sodium-calcium exchange activity in cardiac sarcolemmal vesicles. J. Biol. Chem. 1986, 261(11):4948-4955.
73. Yang J., Chen H., Vlahov I.R., Cheng J.X., Low P.S. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc. Natl. Acad. Sci. USA 2006, 103(37):13872-13877.
74. Go Y.M., Duong D.M., Peng J., Jones D.P. Protein Cysteines Map to Functional Networks According to Steady-state Level of Oxidation. J. Proteom. Bioinform. 2011, 4(10):196-209.
75. Iyer S.S., Ramirez A.M., Ritzenthaler J.D., Torres-Gonzalez E., Roser-Page S., Mora A.L., Brigham K.L., Jones D.P., Roman J., Rojas M. Oxidation of extracellular cysteine/cystine redox state in bleomycin-induced lung fibrosis. Am. J. Physiol. : Lung. Cell Mol. Physiol. 2009, 296(1):L37-L45.
76. Numajiri N., Takasawa K., Nishiya T., Tanaka H., Ohno K., Hayakawa W., Asada M., Matsuda H., Azumi K., Kamata H., et al. On-off system for PI3-kinase-Akt signaling through S-nitrosylation of phosphatase with sequence homology to tensin (PTEN). Proc. Natl. Acad. Sci. USA 2011, 108(25):10349-10354.
77. den Hertog J., Groen A., van der Wijk T. Redox regulation of protein-tyrosine phosphatases. Arch. Biochem. Biophys. 2005, 434(1):11-15.
78. Groen A., Lemeer S., van der Wijk T., Overvoorde J., Heck A.J., Ostman A., Barford D., Slijper M., den Hertog J. Differential oxidation of protein-tyrosine phosphatases. J. Biol. Chem. 2005, 280(11):10298-10304.
79. Himmelfarb J., McMonagle E., Freedman S., Klenzak J., McMenamin E., Le P., Pupim L.B., Ikizler T.A., The P.G. Oxidative stress is increased in critically ill patients with acute renal failure. J. Am. Soc. Nephrol. 2004, 15(9):2449-2456.
80. Scholze A., Rinder C., Beige J., Riezler R., Zidek W., Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation. 2004, 109(3):369-374.
81. Wood Z.A., Schroder E., Robin Harris J., Poole L.B. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 2003, 28(1):32-40.
82. Oberley T.D., Verwiebe E., Zhong W., Kang S.W., Rhee S.G. Localization of the thioredoxin system in normal rat kidney. Free Radic. Biol. Med. 2001, 30(4):412-424.
83. Sunami R., Sugiyama H., Wang D.H., Kobayashi M., Maeshima Y., Yamasaki Y., Masuoka N., Ogawa N., Kira S., Makino H. Acatalasemia sensitizes renal tubular epithelial cells to apoptosis and exacerbates renal fibrosis after unilateral ureteral obstruction. Am. J. Physiol. Renal Physiol. 2004, 286(6):F1030-F1038.
84. Bonventre J.V., Yang L. Cellular pathophysiology of ischemic acute kidney injury. J. Clin. Investig. 2011, 121(11):4210-4221.
85. Pabla N., Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008, 73(9):994-1007.
86. Zhan M., Brooks C., Liu F., Sun L., Dong Z. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology. Kidney Int. 2013, 83(4):568-581.
87. Friedman J.R., Nunnari J. Mitochondrial form and function. Nature. 2014, 505(7483):335-343.
88. Palmer C.S., Osellame L.D., Stojanovski D., Ryan M.T. The regulation of mitochondrial morphology: intricate mechanisms and dynamic machinery. Cell. Signal. 2011, 23(10):1534-1545.
89. Brooks C., Wei Q., Cho S.G., Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J. Clin. Investig. 2009, 119(5):1275-1285.
90. Lombard D.B., Alt F.W., Cheng H.L., Bunkenborg J., Streeper R.S., Mostoslavsky R., Kim J., Yancopoulos G., Valenzuela D., Murphy A., et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol. Cell Biol. 2007, 27(24):8807-8814.
91. Ahn B.H., Kim H.S., Song S., Lee I.H., Liu J., Vassilopoulos A., Deng C.X., Finkel T. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl. Acad. Sci. USA 2008, 105(38):14447-14452.
92. Kong X., Wang R., Xue Y., Liu X., Zhang H., Chen Y., Fang F., Chang Y. Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One 2010, 5(7):e11707.
93. Wu Y.T., Lee H.C., Liao C.C., Wei Y.H. Regulation of mitochondrial F(o)F(1)ATPase activity by Sirt3-catalyzed deacetylation and its deficiency in human cells harboring 4977bp deletion of mitochondrial DNA. Biochim. Biophys. Acta. 2013, 1832(1):216-227.
94. Chen C.J., Fu Y.C., Yu W., Wang W. SIRT3 protects cardiomyocytes from oxidative stress-mediated cell death by activating NF-kappaB. Biochem. Biophys. Res. Commun. 2013, 430(2):798-803.
95. Benigni A., Corna D., Zoja C., Sonzogni A., Latini R., Salio M., Conti S., Rottoli D., Longaretti L. Cassis P, et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J. Clin. Invest. 2009, 119(3):524-530.
96. Morigi M., Perico L., Rota C., Longaretti L., Conti S., Rottoli D., Novelli R., Remuzzi G., Benigni A. Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. J. Clin. Invest. 2015, 125(2):715-726.
97. Klebanoff S.J. Oxygen metabolism and the toxic properties of phagocytes. Ann. Intern. Med. 1980, 93:480-489.
98. S.J. Klebanoff, R.A., Clark Amsterdam: North Holland Biochemical Press, 1978, pp. 447-451.
99. Eiserich J.P., Hristova M., Cross C.E., Jones A.D., Freeman B.A., Halliwell B., van der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998, 391(6665):393-397.
100. Gaut J.P., Byun J., Tran H.D., Lauber W.M., Carroll J.A., Hotchkiss R.S., Belaaouaj A., Heinecke J.W. Myeloperoxidase produces nitrating oxidants in vivo. J. Clin. Investig. 2002, 109(10):1311-1319.
101. Bergt C., Pennathur S., Fu X., Byun J., O'Brien K., McDonald T.O., Singh P., Anantharamaiah G.M., Chait A., Brunzell J., et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. USA 2004, 101(35):13032-13037.
102. Pennathur S., Bergt C., Shao B., Byun J., Kassim S.Y., Singh P., Green P.S., McDonald T.O., Brunzell J., Chait A., et al. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J. Biol. Chem. 2004, 279(41):42977-42983.
103. Hazen S.L., Heinecke J.W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 1997, 99(9):2075-2081.
104. Leeuwenburgh C., Hardy M.M., Hazen S.L., Wagner P., Oh-ishi S., Steinbrecher U.P., Heinecke J.W. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J. Biol. Chem. 1997, 272(3):1433-1436.
105. Kalantar-Zadeh K., Brennan M.L., Hazen S.L. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am. J. Kidney Dis. 2006, 48(1):59-68.
106. Himmelfarb J., McMenamin M.E., Loseto G., Heinecke J.W. Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic. Biol. Med. 2001, 31(10):1163-1169.
107. Malle E., Buch T., Grone H.J. Myeloperoxidase in kidney disease. Kidney Int. 2003, 64(6):1956-1967.
108. Malle E., Woenckhaus C., Waeg G., Esterbauer H., Grone E.F., Grone H.J. Immunological evidence for hypochlorite-modified proteins in human kidney. Am. J. Pathol. 1997, 150(2):603-615.
109. Porubsky S., Schmid H., Bonrouhi M., Kretzler M., Malle E., Nelson P.J., Grone H.J. Influence of native and hypochlorite-modified low-density lipoprotein on gene expression in human proximal tubular epithelium. Am. J. Pathol. 2004, 164(6):2175-2187.
110. Hazen S.L. Myeloperoxidase and plaque vulnerability. Arterioscler. Thromb. Vasc. Biol. 2004, 24(7):1143-1146.
111. Wang Z., Nicholls S.J., Rodriguez E.R., Kummu O., Horkko S., Barnard J., Reynolds W.F., Topol E.J., DiDonato J.A., Hazen S.L. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med. 2007, 13(10):1176-1184.
112. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414(6865):813-820.
113. Cai H. NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ. Res. 2005, 96(8):818-822.
114. Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., Lin J., Bierhaus A., Nawroth P., Hannak D., et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 2003, 9(3):294-299.
115. Dugan L.L., You Y.H., Ali S.S., Diamond-Stanic M., Miyamoto S., DeCleves A.E., Andreyev A., Quach T., Ly S., Shekhtman G., et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J. Clin. Investig. 2013, 123(11):4888-4899.
116. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., Mitch W.E., Harrison D.G. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Investig. 2003, 111(8):1201-1209.
117. Vasquez-Vivar J., Kalyanaraman B., Martasek P., Hogg N., Masters B.S., Karoui H., Tordo P., Pritchard K.A. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. USA 1998, 95(16):9220-9225.
118. Wiggin T.D., Kretzler M., Pennathur S., Sullivan K.A., Brosius F.C., Feldman E.L. Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin-treated DBA/2J mice. Endocrinology 2008, 149(10):4928-4937.
119. Zhang H., Saha J., Byun J., Schin M., Lorenz M., Kennedy R.T., Kretzler M., Feldman E.L., Pennathur S., Brosius F.C. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am. J. Physiol. Renal. Physiol. 2008, 295(4):F1071-F1081.
120. Guzik T.J., Harrison D.G. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov. Today 2006, 11(11-12):524-533.
121. Nakagawa T., Sato W., Glushakova O., Heinig M., Clarke T., Campbell-Thompson M., Yuzawa Y., Atkinson M.A., Johnson R.J., Croker B. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J. Am. Soc. Nephrol. 2007, 18(2):539-550.
122. Zhao H.J., Wang S., Cheng H., Zhang M.Z., Takahashi T., Fogo A.B., Breyer M.D., Harris R.C. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J. Am. Soc. Nephrol. 2006, 17(10):2664-2669.
123. Shu L., Park J.L., Byun J., Pennathur S., Kollmeyer J., Shayman J.A. Decreased nitric oxide bioavailability in a mouse model of Fabry disease. J. Am. Soc. Nephrol. 2009, 20(9):1975-1985.
124. Shu L., Vivekanandan-Giri A., Pennathur S., Smid B.E., Aerts J.M., Hollak C.E., Shayman J.A. Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease. Kidney Int. 2014, 86(1):58-66.
125. Hunt J.V., Dean R.T., Wolff S.P. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem. J. 1988, 256(1):205-212.
126. Huggins T.G., Wells-Knecht M.C., Detorie N.A., Baynes J.W., Thorpe S.R. Formation of o-tyrosine and dityrosine in proteins during radiolytic and metal-catalyzed oxidation. J. Biol. Chem. 1993, 268(17):12341-12347.
127. Huggins T.G., Staton M.W., Dyer D.G., Detorie N.J., Walla M.D., Baynes J.W., Thorpe S.R. o-Tyrosine and dityrosine concentrations in oxidized proteins and lens proteins with age. Ann. NY Acad. Sci. 1992, 663:436-437.
128. Kaur H., Halliwell B. Detection of hydroxyl radicals by aromatic hydroxylation. Methods Enzymol. 1994, 233:67-82.
129. Stern D.M., Yan S.D., Yan S.F., Schmidt A.M. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res. Rev. 2002, 1(1):1-15.
130. Baynes J.W., Thorpe S.R. Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. 2000, 28(12):1708-1716.
131. Baynes J.W., Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999, 48(1):1-9.
132. Miyata T., van Ypersele de Strihou C., Kurokawa K., Baynes J.W. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int. 1999, 55(2):389-399.
133. Miyata T., Ueda Y., Yoshida A., Sugiyama S., Iida Y., Jadoul M., Maeda K., Kurokawa K., van Ypersele de Strihou C. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int. 1997, 51(3):880-887.
134. Miyata T., Fu M.X., Kurokawa K., van Ypersele de Strihou C., Thorpe S.R., Baynes J.W. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia?. Kidney Int. 1998, 54(4):1290-1295.
135. Dyer D.G., Blackledge J.A., Thorpe S.R., Baynes J.W. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J. Biol. Chem. 1991, 266(18):11654-11660.
136. McCance D.R., Dyer D.G., Dunn J.A., Bailie K.E., Thorpe S.R., Baynes J.W., Lyons T.J. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J. Clin. Investig. 1993, 91(6):2470-2478.
137. Monnier V.M. Transition metals redox: reviving an old plot for diabetic vascular disease. J. Clin. Investig. 2001, 107(7):799-801.
138. Sell D.R., Lapolla A., Odetti P., Fogarty J., Monnier V.M. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 1992, 41(10):1286-1292.
139. Pennathur S., Ido Y., Heller J.I., Byun J., Danda R., Pergola P., Williamson J.R., Heinecke J.W. Reactive carbonyls and polyunsaturated fatty acids produce a hydroxyl radical-like species: a potential pathway for oxidative damage of retinal proteins in diabetes. J. Biol. Chem. 2005, 280(24):22706-22714.
140. Brennan M.L., Hazen S.L. Amino acid and protein oxidation in cardiovascular disease. Amino Acids 2003, 25(3-4):365-374.
141. Hazen S.L., Crowley J.R., Mueller D.M., Heinecke J.W. Mass spectrometric quantification of 3-chlorotyrosine in human tissues with attomole sensitivity: a sensitive and specific marker for myeloperoxidase-catalyzed chlorination at sites of inflammation. Free Radic. Biol. Med. 1997, 23(6):909-916.
142. Leeuwenburgh C., Rasmussen J.E., Hsu F.F., Mueller D.M., Pennathur S., Heinecke J.W. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J. Biol. Chem. 1997, 272(6):3520-3526.
143. Pennathur S., Jackson-Lewis V., Przedborski S., Heinecke J.W. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J. Biol. Chem. 1999, 274(49):34621-34628.
144. Pennathur S., Wagner J.D., Leeuwenburgh C., Litwak K.N., Heinecke J.W. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J. Clin. Investig. 2001, 107(7):853-860.
145. Shishehbor M.H., Brennan M.L., Aviles R.J., Fu X., Penn M.S., Sprecher D.L., Hazen S.L. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003, 108(4):426-431.
146. Zheng L., Nukuna B., Brennan M.L., Sun M., Goormastic M., Settle M., Schmitt D., Fu X., Thomson L., Fox P.L., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Investig. 2004, 114(4):529-541.
147. Back S.H., Scheuner D., Han J., Song B., Ribick M., Wang J., Gildersleeve R.D., Pennathur S., Kaufman R.J. Translation attenuation through eIF2alpha phosphorylation prevents oxidative stress and maintains the differentiated state in beta cells. Cell Metab. 2009, 10(1):13-26.
148. Malhotra J.D., Miao H., Zhang K., Wolfson A., Pennathur S., Pipe S.W., Kaufman R.J. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc. Natl. Acad. Sci. USA 2008, 105(47):18525-18530.
149. Okamura D.M., Pennathur S., Pasichnyk K., Lopez-Guisa J.M., Collins S., Febbraio M., Heinecke J., Eddy A.A. CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. J. Am. Soc. Nephrol. 2009, 20(3):495-505.
150. Pop-Busui R., Oral E., Raffel D., Byun J., Bajirovic V., Vivekanandan-Giri A., Kellogg A., Pennathur S., Stevens M.J. Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus. Metabolism 2009, 58(7):989-994.
151. Song B., Scheuner D., Ron D., Pennathur S., Kaufman R.J. Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes. J. Clin. Investig. 2008, 118(10):3378-3389.
152. Vincent A.M., Hayes J.M., McLean L.L., Vivekanandan-Giri A., Pennathur S., Feldman E.L. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009, 58(10):2376-2385.
153. Veiga-Lopez A., Pennathur S., Kannan K., Patisaul H.B., Dolinoy D.C., Zeng L., Padmanabhan V. Impact of gestational bisphenol a on oxidative stress and free fatty acids: human association and interspecies animal testing studies. Endocrinology 2015, 156(3):911-922.
154. Smith C.K., Vivekanandan-Giri A., Tang C., Knight J.S., Mathew A., Padilla R.L., Gillespie B.W., Carmona-Rivera C., Liu X., Subramanian V., et al. Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol. 2014, 66(9):2532-2544.
155. Vivekanandan-Giri A., Slocum J.L., Byun J., Tang C., Sands R.L., Gillespie B.W., Heinecke J.W., Saran R., Kaplan M.J., Pennathur S. High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Ann. Rheum. Dis. 2013, 72(10):1725-1731.
156. Vivekanandan-Giri A., Byun J., Pennathur S. Quantitative analysis of amino Acid oxidation markers by tandem mass spectrometry. Methods Enzymol. 2011, 491:73-89.
157. Sparks M.A., Parsons K.K., Stegbauer J., Gurley S.B., Vivekanandan-Giri A., Fortner C.N., Snouwaert J., Raasch E.W., Griffiths R.C., Haystead T.A., et al. Angiotensin II type 1A receptors in vascular smooth muscle cells do not influence aortic remodeling in hypertension. Hypertension 2011, 57(3):577-585.
158. Meagher E.A., Barry O.P., Lawson J.A., Rokach J., FitzGerald G.A. Effects of vitamin E on lipid peroxidation in healthy persons. J. Am. Med. Assoc. 2001, 285(9):1178-1182.
159. Pennathur S., Pasichnyk K., Bahrami N.M., Zeng L., Febbraio M., Yamaguchi I., Okamura D.M. The macrophage phagocytic receptor cd36 promotes fibrogenic pathways on removal of apoptotic cells during chronic kidney injury. Am. J. Pathol. 2015, 185(8):2232-2245.
160. Heinecke J.W. Is the emperor wearing clothes? Clinical trials of vitamin E and the LDL oxidation hypothesis. Arterioscler. Thromb. Vasc. Biol. 2001, 21(8):1261-1264.
161. Heinecke J.W. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am. J. Cardiol. 2003, 91(3A):12A-16AA.
162. Mashima R., Witting P.K., Stocker R. Oxidants and antioxidants in atherosclerosis. Curr. Opin. Lipidol. 2001, 12(4):411-418.